Blueprint Medicines announces new data from ongoing phase 1 clinical trial of avapritinib
Blueprint Medicines announced new data from its ongoing Phase 1 clinical trial of avapritinib in development for patients with advanced SM. The new data showed strong clinical activity regardless of advanced SM subtype, prior treatment with midostaurin or the presence of additional mutations. December 10, 2017